Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2019

View Archived Issues

TFEB initiates fat cell browning

Diabetes drug eases nicotine withdrawal

SHR-4640: a potential new hyperuricemia treatment option

First-in-class fusion inhibitor against diverse and multidrug-resistant HCV strains presented

Mouse-human chimeric anti-CXADR antibody shows antitumor activity in prostate and SCLC models

Results from multiple phase III studies of anemia treatment roxadustat presented

First patient dosed in phase I/II study of the bicycle toxin conjugate BT-5528

First-in-human data for ASN-007 presented

Urinary TIMP2 and IGFBP7 as early biomarkers to predict drug induced AKI

MG-1131, a novel anti-TIGIT monoclonal antibody with promising in vitro efficacy

Phase I data reported for FPT-155 in patients with advanced solid tumors

Anti-LAG-3 monoclonal antibodies described by Pharmaexplorer, Shanghai Pharmaexplorer

KINE-101, a novel synthetic peptide for rheumatoid arthritis

AlaMab Therapeutics discloses connexin-43 antibodies

Sumitomo Dainippon Pharma patents mGlu2 receptor negative allosteric modulators

Shanghai Leadopharma Technology presents antiepileptic compounds

Sichuan Kelun-Biotech Biopharmaceutical identifies new arginase-1 inhibitors

Phase I/II study of DF-1001 in advanced HER2-expressing sold tumors begins dosing

Bacteriophage "cocktail" fights drinking sequelae, PSC

Phase IIa study of THX-110 in obstructive sleep apnea meets primary endpoint

Pivotal study of Nucala in hypereosinophilic syndrome meets primary endpoint

SQZ-PBMC-HPV begins phase I study in HPV+ recurrent, locally advanced or metastatic solid tumors

Daiichi Sankyo opens enrollment for phase II study of valemetostat in relapsed/refractory ATL

Kiadis terminates development of ATIR-101, refocuses on NK-cell therapy platform

New phase II trial evaluates KN-019 in rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...